MaxCyte Cell & Gene Tech Expo April 2026: Commercial Readiness

As gene-edited cell and gene therapies move from concept to clinic, developers face increasingly rigorous regulatory expectations for safety validation. Achieving regulatory success requires a robust strategy for identifying both on-target and off-target editing events to prevent deleterious outcomes. Modern genotoxicity assessment now relies on a suite of orthogonal, population-informed assays that combine in silico screening with biochemical and cell-based confirmation. This multi-layered approach ensures that rare recombination events, indels, and structural rearrangements are detected across diverse genomic populations, rather than relying on a single reference genome.

By leveraging variant-aware screening and unbiased nomination assays, developers can rank guide RNA candidates early in the discovery phase to mitigate future clinical delays. These methodologies transition seamlessly into the confirmation phase, delivering regulatory-ready reports that categorize off-target risks into actionable tiers. Such a comprehensive evaluation not only supports initial IND filings but also provides the longitudinal data necessary for post-marketing authorization. Discover how these integrated tools can streamline your path to commercialization while ensuring the highest standards of patient safety.

About MaxCyte

MaxCyte® stands at the forefront of cell-engineering, providing the leading non-viral transfection platform powered by our Flow Electroporation® technology, which is instrumental in the discovery and commercialization of cutting-edge cell-based therapies. In 2024, our ExPERT™ electroporation platform is the only proven transfection technology supporting a commercialized non-viral cell therapy. Coupled with our unparalleled scientific, technical, and regulatory support, we enable the complex engineering required for the creation of innovative cell therapies. As a trailblazer in this field for 25 years, we are committed to transforming the future of medicine and helping improve patient outcomes. Let MaxCyte be your partner in navigating the exciting landscape of cell therapy development.